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THE CHANGING ROLE OF VACUUM ASSISTED BIOPSY OF THE BREAST 
Over the past 25 years the diagnosis and management of breast disease has been greatly assisted by 
the development of new needle biopsy techniques with ever improving technology. Fine needle 
aspiration biopsy (FNAB) was quickly superseded in the 1990’s by automated core needle biopsy 
(CNB) techniques and the early 2000’s saw the widespread introduction of vacuum assisted breast 
biopsy (VAB) devices.  
The impetus for the transition from FNAB to CNB was the improved sensitivity and specificity of core 
needle biopsy over the fine needle technique
1,2,
 and the fact that FNAB was associated with a 
significantly high inadequacy rate
3
. CNB also provided superiority of diagnosis in being able to 
distinguish between insitu and invasive malignancy by histological assessment
4 
, and additionally by 
the fact the immunohistochemical and molecular profiling of tumour samples is able to be 
undertaken providing information in relation to ER’s, PR’s and HER 2 for purposes of planning 
systemic treatments and neoadjuvant drug therapies
5
.  Additionally the modern management of 
breast cancer patients importantly necessitates the ability to achieve a tissue diagnosis prior to 
definitive cancer surgery so that proper consultation can be undertaken with the patient being fully 
informed prior to definitive surgical treatment. Indeed current preferred practice would dictate that 
the use of surgical excisional biopsy to establish whether a breast lesion is benign or malignant 
should only be used infrequently and under exceptional circumstances. BreastScreen Australia in its 
National Accreditation Standards requires that more 75% of malignancies should be diagnosed 
without the need for open surgical biopsy
6
.  
Both CNB and VAB offer the ability to achieve a diagnosis nonoperatively for breast lesions, however 
recent reports have demonstrated that VAB may have superiority in certain circumstances in terms 
of its diagnostic ability, and in its capacity to achieve complete excision of breast lesions.  
The vacuum assisted core biopsy device is essentially a core biopsy needle with an associated 
suction chamber and rotating cutter. The vacuum draws tissue into the aperture of the needle, 
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which is then sliced off with a rotating cutter. Whilst some of the earlier VAB devices required the 
needle to be extracted from the breast so that the specimen could be retrieved, most current VAB 
devices transport the specimen by suction into a port chamber without the need to remove the 
needle from the biopsy site, thus enabling multiple tissue samples to be taken through a single skin 
puncture without the need to repeatedly relocate the needle. Vacuum assisted biopsy of the breast 
was first developed in 1995 by Fred Burbank, a Radiologist at Stanford University California, and 
whilst the first commercially available device was the Mammotome marketed by Johnson and 
Johnson, many other similar devices are now available on the market including the Hologic Suros 
Atec and the BARD Encore range of devices. The main advantage of the VAB devices lies in their 
ability to excise large specimens of tissue. For example the standard 14 gauge CNB excises a 
specimen of approximately 20mgs, whereas a 14 gauge VAB needle will extract a sample of 40mgs 
but a 7 gauge VAB needle can extract samples of approximately 300mgs, and with multiples of the 
samples being able to be removed. 
VAB can now be utilized with all of the usual breast imaging modalities including mammography, 
ultrasound and MRI. Ultrasound is the most easily utilized and preferred imaging to guide the 
performance of VAB and from the perspective of the Breast Surgeon who utilizes ultrasound in his 
practice this a readily employable technique. Mammographic stereotactic percutaneous VAB and 
MRI guided VAB are utilized when the breast lesion of concern is only visible on either of these 
modalities. Stereotactic needle biopsy is most commonly used for microcalcification and MRI has a 
particular application in younger women with dense breast parenchyma, particularly those at high 
risk of familial breast cacner.  
In the diagnostic context the indications for VAB are continuing to expand. One of the most useful 
roles of VAB is when there is discordance between the breast imaging findings and the FNAC or core 
biopsy histology.  Wang et al 
7
 in a study of 62 patients in whom lesions were found to be ultrasound 
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imaging-histologic discordant following CNB, the subsequent use of VAB was associated with the 
discovery of malignancy in up to 23% of cases.  
There is also a good argument for advocating the use of VAB for selected cases in BI-RADS Category 
4, particularly 4a, which is associated with a low but significant risk of malignancy in the range of 2-
10%, as VAB has been demonstrated to have a very high negative predictive rate (99%)
8
. 
VAB is also particularly useful in the context of small lesions, including both small sonographic 
lesions < 5mm and very small clusters of microcalcification, both of which are more easily targeted 
with VAB than with a standard CNB. On the other hand microcalcifications of extreme size and 
particularly diffuse areas of pleomorphic microcalcification where DCIS is suspected may be more 
effectively sampled with VAB to improve the probability of detecting or excluding invasive carcinoma 
in the context of a provisional diagnosis of DCIS. A meta-analysis by Brennan
9
 et al which included 52 
studies and 7350 cases of DCIS, the underestimation rate of invasive carcinoma for 14 gauge CNB 
was 30.3% whereas for an 11 gauge VAB this figure was 18.9%.  
VAB is also the preferred method of needle intervention for lesions which are very deep or close to 
the chest wall or very superficial and close the skin or nipple as the VAB mechanism does not involve 
a ‘throw’, as is the case for CNB which may be less safe under these circumstances.  
VAB of the breast has also been demonstrated to have an increasing therapeutic role. In view of the 
large sample size which a VAB device can collect, and as multiple samples can be retrieved at each 
intervention, it is feasible to completely excise breast lesions. The most commonly targeted lesions 
have been fibroadenomas and numerous studies have now been reported utilizing VAB as an 
alternative to surgical excision for the management of fibroadenomata
10,11
. Most studies have 
reported very high success rates with residual or recurrent lesions found in less than 10-15% of 
cases. Lesions up to 2.5cm can be effectively removed using VAB and this is most commonly 
performed under ultrasound guidance.  
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Additionally, there appears to be an increasing role for VAB in the management of atypical B3 types 
of pathological lesions. The pathologic B coding system classifies lesions on core biopsy on a scale of 
B1 (normal and non-diagnostic ) to B5 (malignant) with category B3 being those lesions of uncertain 
malignant potential, and including a range of entities such as atypical epithelial proliferation (AIDEP), 
lobular neoplasia (LN), radial scars/complex sclerozing lesions (RS/CSL), phyllodes tumours (PT), 
papillary lesions  and columnar cell change. In this setting B3 lesions represent a diagnostic and 
therapeutic dilemma making it important to exclude the possibility of malignancy. Published 
literature would suggest that standard CNB has been shown to have an underestimation rate of 
malignancy of approximately 25% for these histological types of lesions
11
 and for this reason 
traditionally surgical excisional biopsy has been recommended. However some reports would 
indicate that VAB does perform better diagnostically than CNB in this setting of B3 lesions, 
particularly for certain types of non-atypical B3 lesions such as papillomas, radial scars and 
fibroepithelial lesions.  
Indeed there have been some recent reports asserting a role for VAB as the definitive means of 
managing many of these B3 lesions and in the context of utilizing VAB as the definitive excision 
method. Strachan et al at Leeds UK
12
 developed clinical pathways for the management of B3 lesions 
both with and without atypia, with VAB being offered as first or second line management, and with 
second line VAB being the equivalent of a diagnostic excision. In this series of 398 patients 245 (62%) 
of women were able to avoid an unnecessary diagnostic excisional biopsy and instead were able to 
be managed by VAB with median follow-up at 3 years showing no evidence of cancer being detected 
at the original B3 site.  
Moreover, a recent international consensus conference
13 
in Switzerland on the management of B3 
breast lesions has recommended a new approach to these lesions incorporating therapeutic VAB in 
lieu of open surgical excision as an acceptable method of management for a range of B3 lesion types 
including flat epithelial atypia (FEA), papillary lesions, radial scars with atypia, benign phyllodes 
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tumours and low grade forms of lobular neoplasia. This heralds a significant strategy shift in the 
management of these types of atypical lesions, and on the basis of the current emerging evidence, 
this approach would appear to be justifiable.  
However as a consequence of the above reports further studies evaluating the role of VAB in this 
context are clearly required, and guidelines would need to be established regarding the 
management of non-concordance between the radiology and any initial biopsy result and the final 
VAB pathology, and recommendations made around the placement of tissue markers  and the 
further management of any unexpected malignancy. The avoidance of open surgery and its 
associated hospital costs would potentially offer significant economic advantages for this new 
approach to managing these types of breast lesions and would undoubtedly offset the additional 
costs of the VAB equipment and needles. 
 
These changed management paradigms, particularly encompassing VAB as a new minimally invasive 
excision tool for benign and atypical breast lesions, will invoke further debate around the issue of 
which specialists should be undertaking such interventions and what training is necessary. As most 
breast abnormalities are sonographically visible, the majority of these interventions would be 
anticipated to be performed under ultrasound control. An important question in particular for Breast 
Surgeons, who have been the traditional interventionalists in breast disease management, is what 
role they will play in this setting. As a Breast Surgeon myself, and one who has utilized ultrasound in 
his clinical practice for the past 20 years and who currently utilizes VAB, I feel it is important that 
Breast Surgeons upskill themselves in ultrasound and needle biopsy techniques to be able to offer 
patients this latest technologically optimal care. Breast Surgeons now have access to numerous 
recognized national and international ultrasound training programs with associated credentialing 
bodies to appropriately facilitate skills development in this area and it would be essential that 
surgeons avail themselves of these programs and achieve the necessary accreditation.   
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